{"id":"placebo-of-tolvaptan","safety":{"commonSideEffects":[]},"_chembl":null,"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Placebo of tolvaptan","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:43:11.699999+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T05:43:27.881483+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:43:19.124281+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Placebo of tolvaptan","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:43:19.554143+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Vasopressin V2 receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:43:21.200749+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL344159/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:43:20.859279+00:00"}},"_dailymed":null,"aiSummary":"Placebo of tolvaptan, marketed by Otsuka Pharmaceutical Co., Ltd., holds a position in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, leveraging Otsuka's reputation and distribution network. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.","mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo is an inert substance designed to be indistinguishable from the active drug in appearance and administration route. It serves as a control arm in randomized controlled trials to assess the efficacy and safety of tolvaptan by comparison against a non-therapeutic baseline, allowing researchers to isolate the true pharmacological effects of the active drug from placebo response effects.","oneSentence":"A placebo formulation containing no active pharmaceutical ingredient, used as a control comparator in clinical trials of tolvaptan.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:01:18.803Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:43:27.881576+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05373264","phase":"PHASE3","title":"HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2024-07-31","conditions":"ADPKD","enrollment":300},{"nctId":"NCT00664014","phase":"PHASE2","title":"A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2008-05","conditions":"Hypovolemic Hyponatremia","enrollment":241},{"nctId":"NCT01733134","phase":"PHASE3","title":"Acute Heart Failure Patients With High Copeptin Treated With Tolvaptan Targets Increased AVP Activation for Treatment (ACTIVATE)","status":"WITHDRAWN","sponsor":"Maisel, Alan, M.D.","startDate":"","conditions":"Acute Heart Failure","enrollment":""},{"nctId":"NCT02964273","phase":"PHASE3","title":"Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2016-09-23","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":91},{"nctId":"NCT03541447","phase":"PHASE2","title":"Tolvaptan-Octreotide LAR Combination in ADPKD","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2018-12-12","conditions":"Autosomal Dominant Polycystic Kidney Disease","enrollment":20},{"nctId":"NCT02476409","phase":"PHASE4","title":"Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2015-07","conditions":"Congestive Heart Failure","enrollment":40},{"nctId":"NCT01552590","phase":"PHASE4","title":"Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites","status":"TERMINATED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2012-04","conditions":"Hyponatremia and Extracellular Fluid in Cirrhotic","enrollment":74},{"nctId":"NCT05060523","phase":"NA","title":"To Study Effect of the Combination of Midodrine and Tolvaptan Versus Tolvaptan Alone in Patients With Severe Hyponatremia in Cirrhosis(TOLMINA Trial)","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2021-09-19","conditions":"Liver Cirrhosis","enrollment":220},{"nctId":"NCT03772041","phase":"PHASE3","title":"Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2019-01-16","conditions":"Congestive Heart Failure","enrollment":294},{"nctId":"NCT03254108","phase":"NA","title":"Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2017-11-06","conditions":"Congestive Heart Failure","enrollment":61},{"nctId":"NCT01199198","phase":"PHASE4","title":"Tolvaptan in Hyponatremic Cancer Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-05","conditions":"Advanced Cancers","enrollment":52},{"nctId":"NCT02331680","phase":"PHASE2","title":"A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2014-12","conditions":"Chronic Renal Failure","enrollment":124},{"nctId":"NCT01439009","phase":"PHASE4","title":"Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2011-09","conditions":"Heart Failure","enrollment":100},{"nctId":"NCT03910231","phase":"PHASE1","title":"The Role of Vasopressin Antagonism on Renal Sodium Handling","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2012-02-01","conditions":"Healthy","enrollment":30},{"nctId":"NCT03803124","phase":"PHASE3","title":"Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD","status":"COMPLETED","sponsor":"Regional Hospital Holstebro","startDate":"2015-12","conditions":"Polycystic Kidney, Autosomal Dominant","enrollment":20},{"nctId":"NCT01451827","phase":"PHASE2","title":"8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2011-10","conditions":"Autosomal Dominant Polycystic Kidney Disease","enrollment":178},{"nctId":"NCT02160145","phase":"PHASE3","title":"Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2014-05","conditions":"Chronic Kidney Disease, Autosomal Dominant Polycystic Kidney Disease","enrollment":1370},{"nctId":"NCT01210560","phase":"PHASE2","title":"Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-10","conditions":"Autosomal Dominant Polycystic Kidney Disease","enrollment":25},{"nctId":"NCT01890694","phase":"PHASE4","title":"Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2012-03","conditions":"Hyponatremia","enrollment":2},{"nctId":"NCT02442674","phase":"PHASE3","title":"A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia","status":"WITHDRAWN","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2015-11","conditions":"Hyponatremia","enrollment":""},{"nctId":"NCT00428948","phase":"PHASE3","title":"Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2007-01","conditions":"Polycystic Kidney Disease, Autosomal Dominant","enrollment":1445},{"nctId":"NCT02352285","phase":"PHASE4","title":"Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure","status":"TERMINATED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2012-12","conditions":"Heart Failure With Hyponatremia","enrollment":58},{"nctId":"NCT02078973","phase":"PHASE2","title":"Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA)","status":"COMPLETED","sponsor":"Regional Hospital Holstebro","startDate":"2014-03-01","conditions":"Nephropathy","enrollment":15},{"nctId":"NCT02527863","phase":"PHASE2","title":"Effect of the Aquaretic Tolvaptan on Nitric Oxide System","status":"COMPLETED","sponsor":"Regional Hospital Holstebro","startDate":"2015-02","conditions":"Autosomal Dominant Polycystic Kidney Disease","enrollment":18},{"nctId":"NCT02644616","phase":"PHASE4","title":"The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement","status":"COMPLETED","sponsor":"Shanghai Chest Hospital","startDate":"2014-11","conditions":"Tricuspid Regurgitation, Right Heart Failure","enrollment":40},{"nctId":"NCT01584557","phase":"PHASE3","title":"Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management","status":"COMPLETED","sponsor":"Cardiovascular Clinical Sciences Inc","startDate":"2012-06","conditions":"Heart Failure","enrollment":250},{"nctId":"NCT02084797","phase":"NA","title":"V2 Receptor Effects on Fluid Regulation and Performance","status":"COMPLETED","sponsor":"Oakland University","startDate":"2011-06","conditions":"Electrolyte Imbalance, Hyponatremia, Hypernatremia","enrollment":10},{"nctId":"NCT02096965","phase":"PHASE1","title":"Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2014-03","conditions":"Nephrolithiasis, Calcium Oxalate, Nephrolithiasis, Calcium Phosphate","enrollment":20},{"nctId":"NCT01663662","phase":"PHASE4","title":"The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study","status":"WITHDRAWN","sponsor":"University of Michigan","startDate":"2012-08","conditions":"Heart Failure","enrollment":""},{"nctId":"NCT01618448","phase":"PHASE3","title":"Efficacy and Safety of Tolvaptan in the Treatment of Cardiac-Induced Edema in Patients With Heart Failure","status":"COMPLETED","sponsor":"Taiwan Otsuka Pharm. Co., Ltd","startDate":"2012-07","conditions":"Cardiac-induced Edema","enrollment":85},{"nctId":"NCT01227512","phase":"PHASE3","title":"Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2010-10","conditions":"Hyponatremia, Dilutional Hyponatremia, Inappropriate ADH Syndrome","enrollment":124},{"nctId":"NCT01638663","phase":"PHASE2","title":"Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TORA)","status":"COMPLETED","sponsor":"Regional Hospital Holstebro","startDate":"2012-05","conditions":"Cardiovascular Diseases, Nephropathy","enrollment":20},{"nctId":"NCT00479336","phase":"PHASE2","title":"A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2007-06","conditions":"Cirrhosis","enrollment":104},{"nctId":"NCT01050530","phase":"PHASE3","title":"A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2009-12","conditions":"Cirrhosis","enrollment":162},{"nctId":"NCT00462670","phase":"PHASE3","title":"A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2007-04","conditions":"Edema, Cardiac","enrollment":110},{"nctId":"NCT01651156","phase":"PHASE3","title":"Efficacy and Safety Study of Tolvaptan to Treat Patients With Cardiac Edema","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2012-07","conditions":"Cardiac Edema","enrollment":244},{"nctId":"NCT00234104","phase":"PHASE2","title":"A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2004-08","conditions":"Heart Failure, Congestive, Edema","enrollment":122},{"nctId":"NCT00525265","phase":"PHASE3","title":"A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2007-09","conditions":"Cardiac Edema","enrollment":20},{"nctId":"NCT01716611","phase":"PHASE4","title":"Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites","status":"UNKNOWN","sponsor":"Konkuk University Medical Center","startDate":"2012-11","conditions":"Hyponatremia, Ascites","enrollment":105},{"nctId":"NCT01349335","phase":"PHASE2","title":"Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2009-04","conditions":"Ascites, Hepatic Cirrhosis","enrollment":180},{"nctId":"NCT01349348","phase":"PHASE3","title":"Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","startDate":"2010-10","conditions":"Ascites, Hepatic Cirrhosis","enrollment":535},{"nctId":"NCT00071331","phase":"PHASE3","title":"EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2003-09","conditions":"Congestive Heart Failure","enrollment":3600},{"nctId":"NCT00201994","phase":"PHASE3","title":"\"SALT-2 Trial\" Study of Ascending Levels of Tolvaptan in Hyponatremia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2003-11","conditions":"Hyponatremia, Water Intoxication, Inappropriate ADH Syndrome","enrollment":243},{"nctId":"NCT00132886","phase":"PHASE2","title":"Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2004-12","conditions":"Heart Failure, Congestive","enrollment":140},{"nctId":"NCT01507727","phase":"PHASE2, PHASE3","title":"Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2012-01","conditions":"Non-hypovolemic Non-acute Hyponatremia","enrollment":240},{"nctId":"NCT00550459","phase":"PHASE3","title":"Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2007-08","conditions":"Hyponatremia","enrollment":57},{"nctId":"NCT01014416","phase":"PHASE1","title":"Pharmacokinetics/Pharmacodynamics (PK/PD) Characteristics of Tolvaptan Tablet in Korean Healthy Male","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","startDate":"2010-01","conditions":"Healthy","enrollment":46},{"nctId":"NCT00072683","phase":"PHASE3","title":"\"SALT Trial\" Study of Ascending Levels of Tolvaptan in Hyponatremia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2003-04","conditions":"Hyponatremias, Water Intoxication, Inappropriate ADH Syndrome","enrollment":240},{"nctId":"NCT00043758","phase":"PHASE2","title":"Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2002-07","conditions":"Congestive Heart Failure","enrollment":170}],"_emaApprovals":[],"_faersSignals":[],"crossReferences":{"chemblId":"CHEMBL344159"},"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Placebo of tolvaptan","genericName":"Placebo of tolvaptan","companyName":"Otsuka Pharmaceutical Co., Ltd.","companyId":"otsuka","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T05:43:27.881576+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}